A composite immune-nutritional and tumor marker score predicts outcomes in LA-ESCC treated with neoadjuvant chemoimmunotherapy and surgery

Key Points

• The study aims to evaluate the efficacy of the GCF score in predicting outcomes for LA-ESCC patients post-treatment.
• Calculated the GCF score using GINI, CYFRA 21-1, and FARI.
• Analyzed outcomes related to disease-free survival (DFS) and pathological response post-neoadjuvant chemoimmunotherapy and surgery.
• Assessed the integration of the GCF score within predictive models for outcome prediction.
• The GCF score independently predicts disease-free survival (DFS) and pathological response.
• Integration of the GCF score into predictive modeling significantly enhances performance.
• The GCF score may serve as a practical, blood-based biomarker for individual risk stratification.